Search

Your search keyword '"Malolepsza, E"' showing total 66 results

Search Constraints

Start Over You searched for: Author "Malolepsza, E" Remove constraint Author: "Malolepsza, E"
66 results on '"Malolepsza, E"'

Search Results

1. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

2. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

3. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

4. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

5. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

6. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

9. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

10. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

11. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

12. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

13. Liver-related death among HIV/hepatitis C virus-co-infected individuals

14. Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression : A prospective cohort study

15. Infection-related and -unrelated malignancies, HIV and the aging population

16. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study

17. Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors

18. Non-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study

19. Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patients

20. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

21. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

22. Development of a definition for rapid progression (RP) of renal function in HIV-positive persons:the D:A:D study

23. Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

24. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

25. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

26. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

27. Limited cross-border infections in patients newly diagnosed with HIV in Europe

28. Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients

29. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

30. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study

31. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

32. A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study

33. A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study

34. History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change

35. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study

36. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies

37. Serious Fatal and Nonfatal Non-AIDS-Defining Illnesses in Europe

38. High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome

39. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

40. Dialysis and renal transplantation in HIV-infected patients: a European survey

42. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations.

43. Protein interaction networks in the vasculature prioritize genes and pathways underlying coronary artery disease.

44. Selection, optimization, and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations.

45. Using brain cell-type-specific protein interactomes to interpret neurodevelopmental genetic signals in schizophrenia.

46. Returning integrated genomic risk and clinical recommendations: The eMERGE study.

47. Multiancestral polygenic risk score for pediatric asthma.

48. Endothelial ARHGEF26 is an angiogenic factor promoting VEGF signalling.

49. Genome-wide polygenic score to predict chronic kidney disease across ancestries.

50. Development and validation of a trans-ancestry polygenic risk score for type 2 diabetes in diverse populations.

Catalog

Books, media, physical & digital resources